Business
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM E
About this update from Cardiff Oncology, Inc.
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025 Time: 4:00 PM ET Interested parties can register for and access the live webcast for the conferences by visiting the “ Events ” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com . Cardiff Oncology Contact: James Levine Chief Financial Officer 858-952-7670 [email protected] Investor Contact: Candice Masse Astr Partners [email protected] Media Contact: Amy Bonanno Lyra Strategic Advisory [email protected]
View stock analysis, news, and events for Cardiff Oncology, Inc.